Ocrevus cut disability worsening in high-risk relapsing MS
By MS Buddy ·
Summarized from Neurology(R) neuroimmunology & neuroinflammation, Jan 2027 · PubMed · DOI. AI-generated summary. Not medical advice.
Clinical trial · 2,370 people with relapsing MS or primary progressive MS
Research by Stephen Hauser, Amit Bar-Or and 10 colleagues at the University of Pennsylvania, the University of California, San Francisco and 1 other institution in Switzerland and the United States.
Did Ocrevus lower disability worsening risk in high-risk relapsing MS?
Key Takeaway
In a high-risk group with relapsing MS, Ocrevus lowered the risk of disability worsening compared with interferon beta.

What They Found
Ocrelizumab (Ocrevus) reduced B cells (immune cells measured in blood) in people with relapsing MS. Longer treatment and greater drug exposure were linked to larger reductions. People with relapsing MS who still had detectable B cells during treatment had more new or growing brain lesions. Among people taking interferon beta, high levels of both B cells and a blood marker identified greater risk of disability worsening. In that high-risk group, Ocrevus was linked to about one-quarter the risk of disability worsening seen with interferon beta.
Who Should Care and Why
The study included people with relapsing MS and people with primary progressive MS in three treatment trials. Researchers examined blood samples taken before and during treatment. They compared B-cell levels with changes seen on brain scans and with disability worsening. In people with primary progressive MS, higher levels of one type of B cell were linked to more shrinkage in part of the brain. The findings connect blood measurements with different outcomes in the two forms of MS.
Important Considerations
You should know the study examined blood samples from 2,370 people in three treatment trials. The high-risk finding concerned a subgroup with relapsing MS, not everyone in the trials. The abstract does not say whether these blood measurements can guide your treatment choices.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Neurology(R) neuroimmunology & neuroinflammation by et al.. Reproduced from the PubMed record.
Anti-CD20 B-cell-depleting therapies demonstrate robust efficacy in people with multiple sclerosis (pwMS). This study addressed the limited understanding of relationships between B-cell populations before and after treatment with ocrelizumab and outcomes in people with relapsing MS (pwRMS) or primary progressive MS (pwPPMS). Total circulating blood B cells and B-cell subsets were examined at baseline and longitudinally in pwRMS and pwPPMS enrolled in the pivotal Phase 3 trials (OPERA I, OPERA II, and ORATORIO). Relationships to disease outcomes before and after treatment with ocrelizumab or comparators were evaluated using generalized linear models and time-to-event analyses. Ocrelizumab rapidly depleted total B cells in pwRMS. Blood samples (n = 15,025) were assessed from 3 Phase 3 trials from 2,370 pwMS, demonstrating depletion in all B-cell subsets. Greater depletion was observed with higher ocrelizumab exposure and longer treatment duration. In limited pwMS with detectable B cells, the majority were mature-naive B cells. Findings from the double-blind treatment period considered robust were that pwRMS with detectable mature-naive, memory, or total B cells had greater risk of developing new/enlarging T2 lesions (odds ratio: 3.8-4.9; p < 0.001), while pwPPMS with higher circulating plasmablasts had greater thalamic volume loss (β: -1.4; p < 0.001). Above-median baseline memory B-cell levels identified interferon beta-1a-treated pwRMS at greater risk of disability progression (hazard ratio: 2.0; p < 0.01), with larger numbers of slowly expanding lesions (p < 0.01). When interferon beta-1a-treated pwRMS presented both high baseline B cells and high serum neurofilament light (NfL; B cells/NfL high), they showed an even higher risk of disability progression (HR: 3.10; p < 0.001). Treatment with ocrelizumab in this subgroup of pwRMS with B cells/NfL high resulted in a near 4-fold reduction in risk of disability progression (HR: 0.25, p < 0.001). Ocrelizumab treatment depleted total B cells and all B-cell subsets in an exposure-dependent and duration-dependent manner. PwRMS with detectable on-treatment B cells had greater risk of new/enlarging T2 lesions, suggesting that sustained deep B-cell depletion may be important for preventing disability worsening. High baseline B cells when present with high NfL identified a population at increased risk of disease worsening who could benefit from ocrelizumab treatment.
Trials you could look into
This study looked at a treatment with MS trials currently recruiting or under way.
Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.
Categories
Explore more research
Related MS research

11/19/2026
A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/19/2026
A review finds lasting control of disease activity after stem cell transplants in selected people wi
Read More
11/19/2026
Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan
Read More
11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
11/14/2026
In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
